The Primer on Anxiety Disorders provides early-stage practitioners and trainees - as well as seasoned clinicians and researchers - with need-to-know information designed to assist in the diagnosis and treatment of anxiety disorders.

Foreword: Anxiety Disorders, Big Science, and Big Data: The Next Generation of Science and Practice ; Section 1: Overview of Anxiety and Related Illnesses ; 1. Anxiety and Related Disorders in DSM5. ; 2. Translational Perspectives, RDoC and Anxiety. ; Section 2: Neurobiology and Neural Circuitry of Anxiety Disorders ; 3. Neurobiology and Neuroimaging of Fear and Anxiety Circuitry. ; 4. The Genetics of Anxiety Disorders. ; Section 3: Development of Fear, Fear Pathways, and Anxiety Disorders in Children and Adolescents ; 5. Developmental Biology related to Emotion and Anxiety. ; 6. Development of Fear and its Inhibition ; 7. Involving the Family in Treatment. ; 8. Treating the College-age Patient. ; Section 4: Posttraumatic Stress and the Neurobiology of Trauma ; 9. PTSD and the Biology of the Stress Response. ; 10. Clinical Aspects of Trauma-related Anxiety and PTSD. ; Section 6: Obsessive Compulsive and Disorders of Cortical-Striatal Processing ; 11. Dissecting OCD Circuits: From Animal Models to Targeted Treatments. ; 12. Clinical aspects of Obsessive Compulsive Disorder. ; Section 7: Phobias, Fears, and Panic ; 13. The Etiology of Fear and Anxiety: The Role of Environmental Exposures. ; 14. Clinical Aspects of Social Anxiety Disorder and Specific Phobias. ; 15. Clinical aspects of Panic disorder. ; Section 8: Intersection of Medical and Anxiety Disorders ; 16. Fear, Anxiety, Avoidance, and Chronic Pain. ; 17. Detection and Treatment of Anxiety Disorders in Primary Care Settings. ; 18. Gastrointestinal Disorders, Irritable Bowel Syndrome, and Anxiety. ; 19. Anxiety Disorders and Cardiovascular Illness. ; Section 9: Intersection of Anxiety with Mood and Substance Disorders ; 20. Substance abuse and Comorbidity with Anxiety. ; 21. Comorbidity of Anxiety and Depression. ; 22. Generalized Anxiety Disorder. ; 23. Anxiety and Suicide. ; Section 10: Cognitive and Exposure Based Treatments of Anxiety Disorders ; 24. Neural Circuitry Mechanisms of Fear Extinction. ; 25. Learning Theory and Cognitive Behavioral Therapy. ; 26. Pharmacological Mechanisms of Modulating Fear and Extinction. ; Section 11: Neurotransmitter Pathways and Pharmacological Treatments of Anxiety Disorders ; 27. Stress, Anxiety, Depression and the Role of Glutamate Neurotransmission. ; 28. The Role of the Hypothalamic-Pituitary-Adrenal Axis in Anxiety Disorders. ; 29. Pharmacological Interventions for Adult Anxiety Disorders. ; Section 12: New Technologies and Approaches to Treatment ; 30. Adherence to Psychotherapy and Pharmacotherapy for Anxiety Disorders. ; 31. Computer Tools as Novel Treatment for Depression and Anxiety. ; 32. Internet-Based Treatment for Anxiety, OCD, and Related Disorders.

"All clinicians and clinical scientists working in anxiety disorders who would like a vision of where the field will be in 5 to 10 years should read this Primer. With three of the leading clinical investigators in the world as Editors, and with a first-rate roster of contributors covering all the latest findings from neurotransmitter underpinnings of drug treatments to the neuroscience of psychological treatments, readers can preview likely changes in diagnosis, assessment, and treatment in the years to come. Most importantly, we get a glimpse of a future in which we can individualize treatment based on a sound set of scientifically validated predictors of outcome. A must read!" - David H. Barlow PhD, ABPP, Professor of Psychology and Psychiatry, Boston University, Founder and Director Emeritus, Center for Anxiety and Related Disorders, Boston, MA "The study of anxiety, once the foundational concept for all psychopathology, maps the path for the future of all psychiatric neuroscience and psychobiology, revealing the rich interplay of nature, nurture and development, and yielding therapeutic advances in psychotherapies, psychopharmacology and neurotherapeutics. The publishers, editors and authors of this volume, and the pioneering organization that has brought them together, the ADAA, have delivered a comprehensive, essential and useful volume for the field." - Jerrold F. Rosenbaum, MD, Chief of Psychiatry, Massachusetts General Hospital; Stanley Cobb Professor of Psychiatry, Harvard Medical School, Boston, MA "Among the book's many strengths are its readability, the focus on the important, need-to-know material, and comprehensive summaries of cited research. " -- Jeremy Petrous, Doody's

Selling point: Authored by leaders in the field of anxiety disorders Selling point: Takes a translational approach moving from basic and mechanistic research to clinical outcomes Selling point: A project of the scientific council of the Anxiety and Depression Association of America

Kerry J. Ressler, Professor of Psychiatry and Behavioral Sciences at Emory University, received his B.S. degree in molecular biology from M.I.T., and his M.D./Ph.D. from Harvard Medical School. His work focuses on translational research bridging molecular neurobiology in animal models with human genetic research. His basic and clinical research examines neurobiological, molecular, genetic and behavioral processes that underlie fear related processing and Posttraumatic Stress Disorder. Dr. Daniel S. Pine is Chief, Section on Development and Affective Neuroscience, in the National Institute of Mental Health Intramural Research Program. Since graduating from medical school at the University of Chicago, Dr. Pine has been engaged continuously in research on pediatric mental disorders. Currently, his group examines the degree to which mood and anxiety disorders in children and adolescents are associated with abnormalities in the amygdala, prefrontal cortex, and brain regions that modulate these structures. Barbara Olasov Rothbaum, Ph.D. is a professor in psychiatry and Associate Vice Chair of Clinical Research at the Emory School of Medicine in the Department of Psychiatry and Behavioral Sciences and director of the Trauma and Anxiety Recovery Program at Emory. Dr. Rothbaum specializes in research on the treatment of individuals with anxiety disorders, particularly focusing on Posttraumatic Stress Disorder (PTSD).

Selling point: Authored by leaders in the field of anxiety disorders Selling point: Takes a translational approach moving from basic and mechanistic research to clinical outcomes Selling point: A project of the scientific council of the Anxiety and Depression Association of America